Interleukin-6 (IL-6) has emerged as a cytokine involved in cachexia progression with some cancers. This review will present the recent breakthroughs in animal models and humans related to targeting IL-6 as a cancer cachexia therapy.
INTRODUCTION
Cancer cachexia is a wasting syndrome that occurs in approximately 80% of cancer patients and is the primary cause of death for 22-30% of all cancer patients [1, 2] . A significant complication related to the prevention of cachexia is that cancer patients are not usually diagnosed with cachexia until they have lost more than 5-7% of body mass [3, 4] . Additionally, the radiochemotherapy used to treat cancer can exacerbate cachexia progression in some patients, which may ultimately affect the patient outcomes [3, 5] . Thus, cancer cachexia can severely diminish the quality of life in cancer survivors because of a severe loss of skeletal muscle mass [1, 6] . Therefore, the future identification of therapies to treat cachexia will not only involve the attenuation of wasting, but also target muscle mass recovery after wasting has occurred. To this end, nutritional or anabolic treatments have only been partially effective in attenuating cachectic muscle mass loss [7] and recovery of muscle mass has not been widely examined. Although several systemic hallmarks (anemia, hypogonadism, and insulin resistance) are associated with cancer cachexia, chronic inflammation has been widely investigated as an important regulator of wasting [1, 8] . Chronic inflammation in cachectic patients is often a combination of both tumor and host derived factors. A multitude of cytokines including TNF-a, IL-1b, interleukin-6 (IL-6), glucocorticoids, and myostatin has been implicated in facilitating a cachectic state [1, 2, 9] . Researchers have been examining the potential cachexia treatments for some time and extensive research has emerged on the role of individual cytokines for regulating cachexia progression in rodent cancer models. IL-6 has emerged a major player in cancer cachexia progression with its levels correlating to survival time in patients [10] . The purpose of this review is to present the recent breakthroughs in animal models and humans related to targeting IL-6 as a therapy for the treatment of cancer cachexia.
INTERLEUKIN-6 SIGNALING: CLASSICAL INTERLEUKIN-6 SIGNALING
IL-6 is a pleiotropic cytokine essential for wound healing and regeneration in mitotic tissues like skin and liver [11] [12] [13] . It is also associated with hypertrophy in postmitotic tissues, such as muscle [14] . IL-6 function involves leukocyte activation, particularly through priming of macrophages toward an anti-inflammatory phenotype. IL-6 has also been implicated in muscle wasting, tumorigenesis, and the production of liver acute-phase proteins (APPs) [15, 16] . These paradoxical effects of IL-6 have been attributed to a temporal function, based on acute versus chronic IL-6 exposure [17] . However, the specific signaling intermediates responsible for the IL-6 signaling profile are not well understood.
The IL-6 cytokine family shares the secondary receptor glycoprotein 130 (gp130). The IL-6-mIL-6R (membrane IL-6 receptor (IL-6R)) complex recruits two gp130 subunits to induce downstream Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) and extracellular regulated MAP kinase (ERK) signaling. STAT-3 phosphorylation leads to the transcription of suppressor of cytokine signaling 3 (SOCS-3) -a negative regulator of IL-6 signaling [18, 19] (Fig. 1 ). Classical IL-6 signaling, limited by the cellular expression of mIL-6R, leads to proliferation, survival, regeneration and acutephase response (APR) in target tissues [20] . However, in chronic conditions like cancer cachexia, prolonged activation of proliferation, survival, and APR can lead to tumorigenesis and hypermetabolism, leading to recruitment of the adaptive immune system and soluble IL-6R (sIL-6R) signaling.
INTERLEUKIN-6 SIGNALING: A ROLE FOR TRANS-SIGNALING
Coupled to the complexity of IL-6 signaling are its farreaching effects on tissues lacking the IL-6R [21, 22] . Acute cellular response to IL-6 under noninflammatory conditions can be limited by the expression level of the mIL-6R [20] [21] [22] . Tissue IL-6 sensitivity can, however, be increased by the 'trans-IL-6 signaling cascade' [21, 22] mediated by the sIL-6R. The sIL-6R is generated by mIL-6R cleavage, also described as IL-6R shedding, and orchestrated by neutrophils and macrophages [21] . Hence, the trans-IL-6 signaling pathway is associated with the proinflammatory effects of IL-6 signaling observed under disease and autoimmune conditions [20] . Thus, inhibition of the mIL-6R alone is insufficient to block IL-6 signaling, and therapies targeting IL-6 regulation of cancer cachexia progression will likely need to account for the differential effects of classical and trans-IL-6 signaling in various tissues [21, 22] .
SKELETAL MUSCLE AS A TARGET OF INTERLEUKIN-6
A large body of work in rodents has demonstrated that muscle wasting with cancer cachexia is a KEY POINTS IL-6 signals through the IL-6-IL-6R-gp130 pathway to activate the JAK-STAT-3 and ERK cascades associated with inflammatory and mitotic processes, respectively. Prolonged activation of these cascades can, however, lead to wasting and tumorigenesis observed during cancer cachexia.
Trans IL-6 signaling mediated by the soluble IL-6R is associated with the proinflammatory effects of IL-6, whereas the membrane-bound receptor is associated with the anti-inflammatory and acute-phase response. Cachexia progression is associated with an elevation of both proinflammatory and acute-phase proteins.
Muscle as a target: inhibition IL-6-IL-6R-STAT-3 cascade can attenuate muscle degradation pathways but does not affect the IL-6-dependent suppression of muscle protein synthesis in cachectic mice. Cachectic patients, however, can induce muscle wasting independent of STAT-3.
Liver and gut as a target: chronic exposure to IL-6 during cachexia progression leads to anemia and elevated plasma CRP and immunoglobulin levels pointing toward hepatic dysfunction. Elevated plasma IL-6 also affects gut microbiota and possibly elevates intestinal permeability with severe cachexia. Further work is needed to elucidate the role of these visceral organs in cachexia progression.
Therapeutic use: targeted inhibition of IL-6 signaling cascade in rodent models attenuated muscle atrophy and has shown potential in human studies by increasing muscle mass, survival time, and quality of life in cachectic patients However, large-scale clinical trials are needed to rule out any side-effects of this treatment.
double-edge sword that involves protein synthesis suppression and activation of several protein degradation pathways [23] [24] [25] [26] . The Apc Min/þ and C26 tumor-implanted mice have an established IL-6dependent loss of skeletal muscle during cancer cachexia [9, 27, 28] . Muscle wasting in these models corresponds with an increase in muscle STAT-3 and nuclear factor kappa B (NF-kB) signaling that is linked to the induction ubiquitin-proteasome degradation and autophagy. In Apc Min/þ mice, Atrogin 1, a muscle-specific E3 ligase, is induced with as little as 5% body weight loss; however, the classical disuse marker muscle RING-finger protein-1 (MURF1) is not increased. As the mice transition to a more cachectic state, when levels of plasma IL-6 are chronically high [29] , ATP-independent mechanisms, such as autophagy, are also involved in skeletal muscle breakdown. In the cachectic Apc Min/þ mouse, both ubiquitin-proteasome and autophagy protein degradation processes can be suppressed by systemic IL-6R antibody (IL-6RAb) administration [29] .
Unlike protein degradation, a clear linkage between IL-6 and STAT-3 activation has not been established for the suppression of muscle protein synthesis (MPS). However, IL-6 may indirectly inhibit MPS via insulin-like growth factor 1 (IGF-1) suppression and AMP-activated kinase (AMPK) activation [25, 29, 30] . Cachexia also induces the loss of muscle mitochondrial content [26, 31] , which may be related to chronic activation of muscle AMPK signaling and mTOR suppression. Administration of an AMPK inhibitor to C2C12 cells attenuates IL-6 inhibition of mTOR signaling [27] . In the cachectic Apc Min/þ mouse, inhibition of IL-6 signaling through systemic administration of IL-6RAb attenuates further body weight and muscle loss without rescuing MPS. Additionally, the activation of mTOR signaling by both glucose and exercise is suppressed in the cachectic Apc Min/þ mouse [23, 26, 27] . However, this may be an indirect effect of IL-6, as IL-6 administration to C2C12 myotubes does not inhibit insulin stimulation of mTOR signaling [27] . Further work is needed to establish whether suppressed MPS is a response to elevated systemic inflammation represented by the classical inflammatory markers like NF-kB signaling pathways. However, simultaneous inhibition of both NF-kB and STAT-3 attenuates MPS suppression in cachectic mice [32] .
Unlike rodent models, the pathways regulating skeletal muscle protein turnover in the cachectic cancer patient have been difficult to ascertain and are still being established. Some recent studies show that induction of autophagy, independent of proteasome pathways, is sufficient to induce wasting in cachectic patients [33, 34] . Additionally, colon cancer patients with reduced muscle mass have demonstrated a trend for increased protein breakdown and decreased induction of postprandial MPS [35] . However, male non-small cell lung cancer patients with elevated IL-6 levels were able to improve whole-body net protein balance through increased synthesis stimulated by hyperaminoacidemia [36] . There is also evidence against STAT3 and NF-kB signaling being associated with the progression of cancer cachexia in abdominal muscle from cancer patients [37] . Such discrepancies between rodent and human signaling cascades, coupled with the genetic polymorphisms in the IL-6-IL-6R genes, could limit the efficacy of preclinical drugs in human trials [37, 38] . Further work is needed to establish whether these differences between cancer patients and rodent models are related to muscle phenotype or the type of cancer.
THE LIVER AS A TARGET OF INTERLEUKIN-6
The liver governs a host of metabolic and inflammatory processes in the body and is known to hypertrophy, as peripheral tissues atrophy in cachectic patients [1, 7, 29] . Given the hypermetabolic and proinflammatory cause of cachexia, disruption of liver functions could play a role in the cachexia progression. Liver expression of TGF-b family transcription factor TSC22D4 correlates with body weight loss and very low-density lipoprotein hyposecretion in the IL-6-dependent C26 cancer cachexia model [39] . Chronic IL-6 exposure during cachexia is also known to induce anemia and produce APPs, which provides further evidence of liver dysfunction [1, 28] . Infact, serum C-reactive protein (CRP), hemoglobin, and immunoglobulin levels are considered while calculating cachexia index in patients [25] . Liver dysfunction related to the disrupted metabolic state with cancer cachexia may also be related to the tumor-induced Warburg effect [1, 28] . Interestingly, hepatic tissue is known to have a higher level of IL-6 expression even under normal disease-free conditions. Constitutively induced hepatic IL-6 expression helps maintain the liver dendritic cells in an immature state and tolerate basal endotoxin exposure from the portal blood. Activation of hepatic dendritic cells can lead to immune cell recruitment and fibrosis [40] . However, loss of systemic IL-6 in mice also leads to liver fibrosis that is associated with insulin resistance and obesity with aging and further complicates the effect of IL-6 on the liver [41] . Thus, liver function could play an important role in cachexia progression, but as cachexia is characterized as a wasting disorder most of the research focuses on muscle and fat tissue restoration, whereas the effect of cachexia progression on the liver, which may directly impact the muscle and fat mass, is largely unknown.
THE GUT AS A TARGET OF INTERLEUKIN-6
The small intestine plays an important role in the absorption of nutrients from the food and its optimal functioning is essential during the hypermetabolic cachectic state. Although altered absorption with cachexia has not been clearly established, Puppa et al. [42] investigated the role of gut barrier dysfunction in the cachectic Apc Min/þ mouse and found an association between increased plasma IL-6 levels and gut permeability. This elevated gut permeability with severe cachexia could point to a disruption of epithelial cell tight junction proteins.
As plasma endotoxin levels were found elevated only in the severely cachectic mice, it can be hypothesized that increased gut permeability could lead to seepage of bacterial endotoxin into the blood stream. However, it is not known whether treatment with IL-6 inhibitors could attenuate gut barrier dysfunction in the cachectic Apc Min/þ mouse. Another emerging research area is the composition of gut microbiota with cancer cachexia [43, 44] . Cachectic mice have suppressed levels of cecal Lactobacillus spp., a bacterium known for its immunomodulatory properties [44] . Restoring the levels of these bacteria led to the suppression of systemic levels of IL-6 and monocyte chemoattractant protein-1, and reduced muscle atrophy by inhibition of both proteasome and autophagy pathways in the gastrocnemius muscle [44, 45] . Thus, modulating the gut bacterial environment can impact cachexia progression in mice. Further research is warranted to elucidate the interactions between muscle, liver, and gut during cachexia progression (Fig. 2) .
INTERLEUKIN-6-TARGETED THERAPEUTICS: PROGRESS IN THE PRECLINICAL MODELS OF CANCER CACHEXIA
Mouse models of cancer cachexia like the Apc Min/þ and C-26 adenocarcinoma implant models have demonstrated a clear dependence on IL-6, with IL-6 signaling inhibition being able to attenuate cachexia progression [1, 2] . However, another widely used mouse implant model, Lewis Lung Carcinoma, has been equivocally related to IL-6 dependence [32] . Recent studies demonstrate the importance of downstream targets of JAK-STAT signaling for the regulation of muscle loss [9] . Inhibition of STAT-3 in vitro abolishes IL-6-induced myotube atrophy [9] ; however, in-vivo studies report an attenuation rather than eradication of muscle wasting. Incomplete inhibition of STAT-3 and STAT-3independent signaling has been implicated in this discrepancy between the in-vivo and the in-vitro results [9] . Until more specific downstream targets of IL-6-induced signaling cascade are identified, inhibition of IL-6R and JAK-STAT-3 intermediates seems to be the best approach to attenuate muscle atrophy during cachexia. IL-6-dependent models of cancer cachexia are also associated with the induction of signaling pathways like NF-kB, AMPK, and Toll-like receptor 4 that are not directly downstream of IL-6 signaling, but are induced as IL-6 levels increase with cachexia progression. Recently, these indirect pathways have been examined for their effect on IL-6-dependent cachexia. Inhibition of NF-kB along with STAT-3 by pyrrolidine dithiocarbamate (PDTC) is able to attenuate the suppression of protein synthesis in cachectic mouse muscle [23] . Quercetin, a dietary flavanol, can suppress systemic inflammation by inhibition of NF-kB in cachexia models [46] . In Apc Min/þ mouse, however, quercetin attenuated muscle atrophy by lowering plasma IL-6 and muscle STAT-3 activation, independent of muscle NF-kB activation [47] . This suggests that in models of IL-6-induced cachexia, NF-kB activation is additive but not essential to regulate muscle wasting. There may also be a role for indirect IL-6 signaling through muscle AMPK activation, which can suppress muscle mTOR-S6 signaling related to protein synthesis [24, 27] . Interestingly, exercise may be beneficial for countering the effects of IL-6 on muscle wasting [48] . Treadmill exercise ablates IL-6-induced body weight and muscle loss in Apc Min/þ mice, even though muscle STAT-3 and NF-kB signaling are activated [17] . There is the possibility that the chronic inflammatory response thought to be detrimental with cachexia could be modulated by altering the indirect effects of IL-6 in the various target tissues during cancer cachexia (Fig. 2) .
INTERLEUKIN-6-TARGETED THERAPEUTICS: CLINICAL STUDIES
Advanced and terminal cancer patients have exhibited elevated levels of plasma IL-6, which have correlated with body weight loss in these patients and are associated with anemia, anorexia, and depression [49] . Clinical trials with drugs such as ghrelin, and thalidomide combined with megestrol acetate do not directly target IL-6, but have demonstrated promise by attenuating some cachectic symptoms in cancer patients, such as appetite, weight gain, and a feeling of well being [50] [51] [52] . However, these therapies have the potential to indirectly suppress systemic IL-6 levels or muscle IL-6 production [51, 53] . The recent targeted human therapies for cachexia related to IL-6 have been focused on developing humanized antibodies that could rescue cachexia symptoms. Earlier attempts with IL-6 antibodies have had some success rescuing lean body mass; however, its effect on muscle mass is unknown and could be misleading as visceral organs hypertrophy in cachexia [49, 53, 54] . Recent clinical studies against humanized IL-6RAb, tocilizumab, have been promising, demonstrating attenuated muscle loss, reduced plasma IL-6 levels, and a restoration of plasma albumin levels, without altering tumor proliferation in humans [3, 55, 56] . However, the side-effects of these studies need to be evaluated as suppression of IL-6 can compromise the immune response to infection affecting patient's recovery and quality of life [57] .
CONCLUSION
Recent research in animal models and cancer patients has further established IL-6's involvement in the regulation of cachexia progression with some cancers. Additionally, IL-6 trans-signaling through the sIL-6R has the potential to amplify IL-6 signaling in cachectic patients. Chronic IL-6 exposure has also shown to induce wasting in skeletal muscle by both direct and indirect activation of pathways involved in protein turnover, metabolism, and inflammation. However, the majority of cachexia research in preclinical studies is concentrated on the physiology of skeletal muscle, whereas the effect of IL-6 signaling on organs like liver and gut are still being elucidated. IL-6 remains a promising therapeutic strategy for attenuating cachexia progression and has the potential to affect the patient's quality of life.
